MedTrace Logo

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

NCT00146211 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2007-12-27

No results posted yet for this study

Summary

This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.

Conditions

  • Huntington Disease

Interventions

DRUG

Ethyl-EPA (Miraxion™)

Sponsors & Collaborators

  • Huntington Study Group

    collaborator NETWORK

  • Amarin Neuroscience Ltd

    lead INDUSTRY

Principal Investigators

  • Ira Shoulson, MD · Huntington Study Group/University of Rochester

  • Christopher Ross, MD, PhD · Huntington Study Group/Johns Hopkins University School of Medicine

  • Blair Leavitt, MD · Huntington Study Group/University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-08-31
Completion
2007-07-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00146211 on ClinicalTrials.gov